FDA Grants Fast Track Designation to Apnimed Sleep Apnea Drug Candidate AD109
Apnimed’s AD109 has the potential to be the first oral pharmacologic that treats OSA airway obstruction at night.
Apnimed’s AD109 has the potential to be the first oral pharmacologic that treats OSA airway obstruction at night.
Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, has named David P. White, MD, senior vice president of medical affairs. In this role, White will...